Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Evelo Biosciences Inc is a biotechnology business based in the US. Evelo Biosciences shares (EVLO) are listed on the NASDAQ and all prices are listed in US Dollars. Evelo Biosciences employs 122 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $2.15 |
|---|---|
| 52-week range | $1.42 - $14.20 |
| 50-day moving average | $2.15 |
| 200-day moving average | $5.13 |
| Wall St. target price | $17.75 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-2.32 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.15 from 2022-07-01
| 1 week (2022-06-27) | -3.15% |
|---|---|
| 1 month (2022-06-02) | -19.48% |
| 3 months (2022-04-04) | -39.44% |
| 6 months (2022-01-03) | -67.57% |
| 1 year (2021-07-02) | -83.38% |
|---|---|
| 2 years (2020-07-02) | -57.26% |
| 3 years (2019-07-03) | 8.55 |
| 5 years (2017-06-30) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -68.83% |
| Return on equity TTM | -348.67% |
| Profit margin | 0% |
| Book value | $0.16 |
| Market capitalisation | $232 million |
TTM: trailing 12 months
We're not expecting Evelo Biosciences to pay a dividend over the next 12 months.
Over the last 12 months, Evelo Biosciences's shares have ranged in value from as little as $1.419 up to $14.2. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Evelo Biosciences's is 1.7688. This would suggest that Evelo Biosciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Evelo Biosciences, Inc. , a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also develops EDP1867, an inactivated investigational oral biologic, which is in Phase 1b for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. .
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.